Cyagen's Chinese research product spinoff raised $40.5m and will use the funding to grow its business along with its contract research services.

University of Pennsylvania-linked Passage Bio issued 4.6 million more shares than originally planned to raise $216m, up more than 70% on its $125m original target.

Stem cell medicine and skincare product developer has added $12.5m as part of a series B-2 round that will come after $15m from SFC two years ago.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Takeda has bought UW spinout PvP Biologics, three years after acquiring an option to buy it in return for $35m in financing.

Nottingham-founded Excellerate Biosciences has been bought by Oxford's spinout OMass Therapeutics, which unveiled a series A extension last week.

Takeda has bought celiac disease therapy developer PvP Biologics, three years after acquiring an option to buy it in return for $35m in financing.

MPM Oncology Innovations Fund will invest half of its corpus in Dana-Farber's oncology pipeline, backing 15 cancer-related startups altogether.

Existing investor Hadasit Bio-Holdings took part in a round that pushed the immuno-oncology therapy developer's overall funding tally to more than $35m.

Cleveland Clinic and Ascension Ventures contributed to a $15.8m round for Cardionomic, which is developing a neuromodulation system to treat heart failure.